Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

In order to assess the effect of scheduling of chemotherapy on the outcome of patients with limited small-cell lung cancer (SCLC), the Clinical Trials Group of the National Cancer Institute of Canada carried out a randomized trial comparing the alternation of cyclophosphamide, Adriamycin (Adria Laboratories, Columbus, OH; doxorubicin) and vincristine (CAV) with etoposide (VP-16) and cisplatin for six cycles to the administration of these two combinations in a sequential fashion (three cycles of CAV followed by three of VP-16/cisplatin). Three hundred eligible patients were enrolled on the trial from September 1981 to October 1984. All responding patients were also treated after completion of chemotherapy with thoracic irradiation in randomly allocated doses of 2,000 and 3,750 cGy. The complete response (CR) rate to chemotherapy was slightly, but not significantly, higher on the alternating arm (52% v 44%, P = .20). However, there was no difference in disease-free or overall survival on the alternating and sequential arms, respectively (47.3 weeks v 45.1 weeks, P = .26; 61.7 weeks v 59.5 weeks, P = .56). Data on the effect of radiotherapy dose on survival are not yet mature, but it does not appear the results of this portion of the trial will alter the interpretation of the chemotherapy comparison. Patient characteristics favorably influencing survival were female sex, good performance status, younger age, and absence of supraclavicular node involvement. Two interpretations of these and other results in SCLC are suggested: (1) the difference between the schedules used is too small for the predictions of the Goldie-Coldman model to be realized in a trial of this size, or (2) VP-16/cisplatin is actually a superior regimen and any schedule that exposes patients to these drugs early in treatment will produce improved results.

[1]  P. Band,et al.  Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung. , 1986, Seminars in oncology.

[2]  Goldie Jh,et al.  Application of theoretical models to chemotherapy protocol design. , 1986 .

[3]  D. Osoba,et al.  VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Arriagada,et al.  Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease. , 1985, International journal of radiation oncology, biology, physics.

[5]  D. Ettinger,et al.  Long-term survivors of small cell carcinoma of the lung. , 1985, The American journal of medicine.

[6]  D. Johnson,et al.  Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. , 1985, Cancer treatment reports.

[7]  J. Mann,et al.  Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. , 1985, Cancer treatment reports.

[8]  D. Osoba,et al.  Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Scher,et al.  Controversies in treatment of small cell carcinoma of the lung. , 1985, Cancer investigation.

[10]  D. Ihde.  Current status of therapy for small cell carcinoma of the lung , 1984, Cancer.

[11]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[12]  H. Hansen,et al.  Cyclic alternating 'non-cross resistant' chemotherapy in the management of small cell anaplastic carcinoma of the lung. , 1984, Cancer Treatment Reviews.

[13]  J. Herman,et al.  Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Minna,et al.  Small cell lung cancer 1973-1983: early progress and recent obstacles. , 1984, International journal of radiation oncology, biology, physics.

[15]  F. Hirsch,et al.  Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. , 1983, Cancer research.

[16]  G. Bonadonna.  Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. , 1982, Cancer research.

[17]  D. Ettinger,et al.  Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP‐16 in small‐cell carcinoma of the lung , 1982, Cancer.

[18]  Goldie Jh,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982 .

[19]  D. V. Van Echo,et al.  Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. , 1982, Cancer treatment reports.

[20]  T. Fleming,et al.  Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer , 1981, Cancer.

[21]  R. Sonntag,et al.  Chemotherapy of small cell carcinoma of the lung: comparison of a cyclic alternative combination with simultaneous combinations of four and seven agents. , 1981, European journal of cancer & clinical oncology.

[22]  G. Deboer,et al.  Combined modality treatment of small cell carcinoma of the lung. , 1981, Archives of internal medicine.

[23]  O. Selawry,et al.  A controlled clinical trial testing two potentially non-cross-resistant chemotherapeutic regimens in small-cell carcinoma of the lung. , 1981, Chest.

[24]  R. Buchanan,et al.  Alternating non-cross-resistant drug combinations in the treatment of metastatic small-cell carcinoma of the lung. , 1981, Cancer clinical trials.

[25]  R. Wittes,et al.  cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. , 1979, Cancer treatment reports.

[26]  R. Livingston,et al.  Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. , 1978, Annals of internal medicine.